- Home
- TNGX vs SNN Comparison
TNGX vs SNN Comparison
Compare TNGX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SNN
- Stock Information
- Founded
- TNGX 2014
- SNN 1856
- Country
- TNGX United States
- SNN United Kingdom
- Employees
- TNGX N/A
- SNN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- TNGX Health Care
- SNN Health Care
- Exchange
- TNGX Nasdaq
- SNN Nasdaq
- Market Cap
- TNGX 351.2M
- SNN 13.2B
- IPO Year
- TNGX N/A
- SNN 1999
- Fundamental
- Price
- TNGX $6.13
- SNN $30.08
- Analyst Decision
- TNGX Strong Buy
- SNN Hold
- Analyst Count
- TNGX 6
- SNN 3
- Target Price
- TNGX $12.20
- SNN $27.50
- AVG Volume (30 Days)
- TNGX 2.7M
- SNN 1.2M
- Earning Date
- TNGX 08-06-2025
- SNN 07-31-2025
- Dividend Yield
- TNGX N/A
- SNN 2.38%
- EPS Growth
- TNGX N/A
- SNN 56.15
- EPS
- TNGX N/A
- SNN 0.47
- Revenue
- TNGX $40,990,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- TNGX N/A
- SNN $6.87
- Revenue Next Year
- TNGX N/A
- SNN $5.19
- P/E Ratio
- TNGX N/A
- SNN $32.18
- Revenue Growth
- TNGX 10.09
- SNN 4.70
- 52 Week Low
- TNGX $1.03
- SNN $23.69
- 52 Week High
- TNGX $12.02
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- TNGX 71.70
- SNN 50.55
- Support Level
- TNGX $5.75
- SNN $29.50
- Resistance Level
- TNGX $6.40
- SNN $31.43
- Average True Range (ATR)
- TNGX 0.48
- SNN 0.41
- MACD
- TNGX -0.04
- SNN -0.03
- Stochastic Oscillator
- TNGX 75.62
- SNN 24.02
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.